Genmab — Oktober 2014
-
+6% er længe siden vi sidst har set
-
Revlimid det 10 dyreste lægemiddel pr. patient i verden: http://www.fiercepharma.com/special-reports/top-10-most-expensive-drugs-2013 Alexions lægemiddel klart dyrest
-
Dette interview William R. Strohl (VP hos Janssen) er ret interessant - http://www.bizjournals.com/philadelphia/blog/health-care/2014/08/why-the-next-big-biologic-may-be-found-by-montco.h
tml -
-
Strohl said one of the difficulties in developing bispecific antibodies is overcoming manufacturing hurdles. “Most can’t be manufactured,” he said. “I have to say we were a little frustrated that we couldn’t develop, internally, a technology that could be trusted to be manufacturable.”
Genmab’s technology proved to be the most promising solution. “We now have 20 bispecific licenses with them,” Strohl said.
-
Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT’s three OmniAb
platforms, OmniRat
, OmniMouse and OmniFlic
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind